Arcellx, Inc. - Common Stock (NQ:ACLX)

115.07 UNCHANGED

Last Price Updated: 4:15 PM EDT, Apr 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 06, 2024

Via Benzinga

Navigating 7 Analyst Ratings For Arcellx ↗

November 06, 2024

Via Benzinga

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

November 05, 2024

From Arcellx, Inc.

Via Business Wire

Cracking The Code: Understanding Analyst Reviews For Arcellx ↗

October 22, 2024

Via Benzinga

4 Analysts Assess Arcellx: What You Need To Know ↗

October 18, 2024

Via Benzinga

Assessing Arcellx: Insights From 7 Financial Analysts ↗

August 09, 2024

Via Benzinga

Decoding 8 Analyst Evaluations For Arcellx ↗

July 22, 2024

Via Benzinga

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024 ↗

August 09, 2024

ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

August 08, 2024

From Arcellx, Inc.

Via Business Wire

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals ↗

July 04, 2024

Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.

Via InvestorPlace

Arcellx Stock Earns Relative Strength Rating Upgrade ↗

June 21, 2024

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.

Via Investor's Business Daily

The Latest Analyst Ratings For Arcellx ↗

June 18, 2024

Via Benzinga

Expert Ratings For Arcellx ↗

May 31, 2024

Via Benzinga

Analyst Expectations For Arcellx's Future ↗

May 14, 2024

Via Benzinga

Peering Into Arcellx's Recent Short Interest ↗

April 15, 2024

Via Benzinga

Arcellx Analysts Boost Their Forecasts After Q4 Results ↗

February 29, 2024

Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday.

Via Benzinga

7 Biotech Stocks to Put on Your Breakthrough Radar ↗

May 27, 2024

Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.

Via InvestorPlace

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 09, 2024

From Arcellx, Inc.

Via Business Wire

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 09, 2024

From Gilead Sciences, Inc.

Via Business Wire

Arcellx Provides First Quarter 2024 Financial Results

May 09, 2024

From Arcellx, Inc.

Via Business Wire

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine ↗

May 09, 2024

These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.

Via InvestorPlace

Arcellx to Participate in Two Upcoming Investor Conferences

May 07, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 04, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

March 20, 2024

From Arcellx, Inc.

Via Business Wire

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

The 3 Biotech Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Via InvestorPlace

Decoding Bearish Analog And The Warning Signs You Can't Ignore ↗

February 07, 2024

A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore.

Via Talk Markets

Topics Stocks

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market ↗

January 16, 2024

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

Via InvestorPlace

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗

January 04, 2024

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.